跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,270 条关于
“KEYNOTE-716”
全部
2,270
临床试验
1,332
药物
496
机构
7
资讯
435
去年
Adjuvant PD-1 Inhibitors Show Promise in Stage IIB/C Melanoma Treatment, KEYNOTE-716 and CheckMate 76K Trials Reveal
去年
Ontada Presents 14 Real-World Evidence Studies at ISPOR 2025 to Advance Cancer Care Research
去年
Strand Therapeutics Appoints Cancer Immunotherapy Pioneer Dr. Jason Luke as Chief Medical Officer
2年前
Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC
4个月前
Sun Pharma's Glaucoma Drug PDP-716 Receives FDA Complete Response Letter Due to Manufacturing Facility Issues
2年前
KEYNOTE-789: Pembrolizumab Plus Chemotherapy Fails to Improve Survival in EGFR-Mutated NSCLC
去年
Pembrolizumab Plus Chemotherapy Improves Overall Survival in HER2-Positive Gastric Cancer
2年前
Pembrolizumab Demonstrates Sustained Survival Benefits in Advanced Melanoma After 10-Year Follow-Up
2年前
Pembrolizumab Improves Overall Survival in Clear Cell Renal Cell Carcinoma
3个月前
The Evolving Role of Biotechnology Keynote Speakers in Shaping Pharmaceutical R&D Strategy
第 1 页,共 44 页
上一页
下一页